STOCK TITAN
  1. Home
  2. News
  3. MIRM

Mirum Pharmaceuticals - MIRM STOCK NEWS

Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.

Mirum Pharmaceuticals, Inc. (symbol: MIRM) is a biopharmaceutical company headquartered in Foster City, California. Established in 2018, the company focuses on the development and commercialization of innovative therapies aimed at treating debilitating liver diseases. Mirum Pharmaceuticals is dedicated to addressing rare and orphan diseases, making significant strides in this niche sector of the healthcare market.

At the core of Mirum Pharmaceuticals' product pipeline is Maralixibat, an investigational oral drug currently in phase 3 clinical trials. Maralixibat is being studied for its efficacy in treating several severe liver conditions, including Progressive Familial Intrahepatic Cholestasis (PFIC), Alagille Syndrome (ALGS), and Biliary Atresia. This product represents a potential breakthrough in providing therapeutic options for these challenging conditions.

In addition, the company has developed Volixibat, a drug aimed at treating Intrahepatic Cholestasis of Pregnancy (ICP) and Primary Sclerosing Cholangitis (PSC). These ongoing projects highlight Mirum Pharmaceuticals' commitment to advancing the treatment landscape for liver diseases with significant unmet medical needs.

Mirum Pharmaceuticals has achieved notable milestones, such as the approval of Livmarli, an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor. Livmarli is approved for the treatment of cholestatic pruritus in patients with Alagille Syndrome (ALGS), providing much-needed relief for those affected by this condition.

The company stands out for its strategic approach to identifying, acquiring, and developing novel therapies. It has established partnerships and collaborations to bolster its research endeavors and expand its reach in the biopharmaceutical industry. With a robust pipeline and a clear focus on debilitating liver diseases, Mirum Pharmaceuticals continues to make significant progress in its mission to improve patient outcomes and quality of life.

For the latest news and updates about Mirum Pharmaceuticals, including recent achievements, ongoing projects, and financial performance, investors and stakeholders can rely on resources like StockTitan for comprehensive and timely information.

Stay informed about Mirum Pharmaceuticals, Inc. and its groundbreaking work in the biopharmaceutical sector, and keep track of the latest developments and stock performance on StockTitan.

News

Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (MIRM) receives FDA approval for LIVMARLI, an oral solution for cholestatic pruritus in PFIC patients. The approval is based on the Phase 3 MARCH study, showing significant reduction in pruritus severity. LIVMARLI also approved for Alagille syndrome. Immediate availability in the U.S. and plans for label expansion for younger patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
fda approval
-
News

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Mirum Pharmaceuticals, Inc. granted inducement awards to new employees, including stock options and restricted stock units. The awards are subject to vesting conditions over several years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
none
-
News

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (MIRM) will participate in upcoming investor conferences, including Leerink Partners Global Biopharma Conference 2024 and Barclays Global Healthcare Conference 2024. The company aims to showcase its novel therapies for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
conferences
News

Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI

Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (MIRM) announces a significant 70% risk reduction in long-term clinical outcomes for patients with Alagille syndrome (ALGS) treated with LIVMARLI. The data show a six-year transplant-free survival benefit, marking a milestone in pharmacological intervention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
none
-
News

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (MIRM) reported strong financial results for Q4 and year-end 2023 with net product sales of $178.9 million and full-year revenue of $186.4 million, showing 142% growth over 2022. Expecting global net product sales of $310-320 million in 2024. Key milestones include LIVMARLI PFIC PDUFA date on March 13, 2024, and interim analyses for Volixibat VISTAS and VANTAGE in first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
earnings
-
News

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024

Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (MIRM) will report Q4 and year-end 2023 financial results on February 28, 2024, followed by a conference call to discuss financial results and corporate progress. Details for the call provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
earnings
News

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Mirum Pharmaceuticals, Inc. grants inducement awards to new employees involving stock options and restricted stock units. The awards are material to employment and align with Nasdaq rules, with options priced at $27.98 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.97%
Tags
none
-
News

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Mirum Pharmaceuticals, Inc. announces the approval of an inducement grant of non-qualified stock options and restricted stock units for their new Chief Medical Officer, Dr. Joanne Quan. The grant includes 75,000 shares of common stock and 37,500 RSUs under Mirum's 2020 Inducement Plan. The stock options have an exercise price of $26.72 per share and will vest over four years, while the RSUs will vest over three years. This grant was approved as an inducement material to Dr. Quan's employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
-
News

Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer

Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has appointed Dr. Joanne Quan as Chief Medical Officer to lead the global clinical development, clinical operations, and safety programs for their pipeline of programs addressing rare diseases. In addition, Peter Radovich has been promoted to President and Chief Operating Officer, overseeing commercial, corporate development, and supply chain functions. Dr. Quan brings nearly three decades of experience in the development of medications for rare conditions, and her appointment strengthens the team and leadership in rare disease at Mirum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
management
News

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) granted inducement awards to seven new employees, consisting of non-qualified stock options to purchase 50,950 shares of common stock and 25,480 restricted stock units under Mirum’s 2020 Inducement Plan. Each stock option has an exercise price per share equal to $26.26 per share and will vest over four years, while the RSUs will vest over three years. The awards are subject to the terms and conditions of Mirum’s 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
none

FAQ

What is the current stock price of Mirum Pharmaceuticals (MIRM)?

The current stock price of Mirum Pharmaceuticals (MIRM) is $47.57 as of February 28, 2025.

What is the market cap of Mirum Pharmaceuticals (MIRM)?

The market cap of Mirum Pharmaceuticals (MIRM) is approximately 2.3B.

What is the focus of Mirum Pharmaceuticals, Inc.?

Mirum Pharmaceuticals focuses on developing and commercializing therapies for debilitating liver diseases, particularly rare and orphan conditions.

What is Maralixibat used for?

Maralixibat is an investigational oral drug for treating Progressive Familial Intrahepatic Cholestasis (PFIC), Alagille Syndrome (ALGS), and Biliary Atresia.

Where is Mirum Pharmaceuticals headquartered?

Mirum Pharmaceuticals is headquartered in Foster City, California.

What is Livmarli?

Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor approved for treating cholestatic pruritus in patients with Alagille Syndrome (ALGS).

When was Mirum Pharmaceuticals founded?

Mirum Pharmaceuticals was founded in 2018.

What is Volixibat being developed for?

Volixibat is being developed to treat Intrahepatic Cholestasis of Pregnancy (ICP) and Primary Sclerosing Cholangitis (PSC).

What are the recent achievements of Mirum Pharmaceuticals?

Recent achievements include the approval of Livmarli for treating cholestatic pruritus in ALGS patients and ongoing phase 3 trials for Maralixibat.

How does Mirum Pharmaceuticals contribute to the biopharmaceutical industry?

Mirum Pharmaceuticals contributes by developing novel therapies for rare liver diseases and establishing strategic partnerships to advance research.

How can I get the latest updates on Mirum Pharmaceuticals?

You can stay informed about the latest updates and stock performance of Mirum Pharmaceuticals on platforms like StockTitan.

What products are in Mirum Pharmaceuticals' pipeline?

Products in the pipeline include Maralixibat for PFIC and ALGS and Volixibat for ICP and PSC.
Stock MIRM logo
Mirum Pharmaceuticals

Nasdaq:MIRM

MIRM Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

MIRM Stock Data

2.30B
39.92M
2.24%
115.72%
13.85%
Biotechnology
Pharmaceutical Preparations
Link
United States
FOSTER CITY